AstraZeneca has received U.S. approval for its new hypertension drug Baxfendy (baxdrostat), a first‑in‑class aldosterone synthase inhibitor that targets a key hormonal driver of high blood pressure in adults whose hypertension remains uncontrolled despite other medications.
Clinical data show Baxfendy added to standard therapy produced placebo‑adjusted seated systolic reductions of 8.7–9.8 mmHg at 12 weeks, with generally mild side effects such as hyperkalemia, hyponatremia, hypotension, dizziness, and muscle spasms.
The approval positions Baxfendy as a novel add‑on option for the large U.S. population with uncontrolled or treatment‑resistant hypertension and opens the door to a new class of aldosterone‑targeting blood‑pressure agents, with competitors like Mineralys Therapeutics’ lorundrostat under review for a December 2026 decision.
Sources:
AstraZeneca wins nod for blood pressure pill, opening new class of ...
New medication lowered hard-to-control high blood pressure in ...
FDA Approves Baxdrostat for Inadequately Controlled Hypertension
FDA approves AstraZeneca's new kind of hypertension drug
US regulator greenlights AstraZeneca's blood pressure drug Baxfendy | Financial News
FDA grants priority review for AstraZeneca's hypertension drug baxdrostat
New hypertension option as Astrazeneca's Baxfendy wins FDA nod
FDA Decision on Baxdrostat Would Bring First ASI to Market
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
AstraZeneca News | Latest News - NewsNow
FDA fast-tracks AstraZeneca's new hypertension drug
AstraZeneca receives FDA approval for hypertension drug Baxfendy
AstraZeneca Gets U.S. Approval for Hypertension Drug - Morningstar